REVENUE (Tables)

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Net Revenue

The following table reflects total revenue, net for the three months ended March 31, 2024 and 2023 (in thousands): 

	Three Months Ended March 31,
	2024		2023
Product sales, net:
ROLVEDON	$	14,478	$	—
INDOCIN products	8,682		30,346
Sympazan	2,617		2,502
Otrexup	2,882		2,822
SPRIX	1,437		1,889
CAMBIA	1,256		2,264
Other products	510		1,946
Total product sales, net	31,862		41,769
Royalties and milestone revenue	586		697
Total revenues	$	32,448	$	42,466